drugset / Trial / NCT06551844
Adaptive Dengue Antiviral Platform Trial
Phase 2
Recruiting
500 enrolled
Oxford University Clinical Research Unit, Vietnam
Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam · collabUniversity Malaya Medical Centre, Malaysia · collab
RandomizedSequentialOpen-labelTreatment
Summary
This is a randomized, open-label adaptive platform trial aiming to screen the antiviral effectiveness of the experimental drug(s) in early dengue infection * Primary objectives: * To determine the antiviral effectiveness of the experimental drug(s) in early dengue infection * To assess the safety and tolerability of the experimental drug(s) in dengue patients * Secondary objective: * To assess the effect of the experimental drug(s) in dengue patients on physiological, clinical and virological parameters
Timeline
- Start
- 2026-04-20
- Primary completion
- 2029-12-31
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Molnupiravir | Small molecule | 800 mg | Oral |
| Subject | Remdesivir | Small molecule | 2.5 mg/kg | Intravenous |
| Subject | Remdesivir | Small molecule | 100 mg | Intravenous |
| Subject | VIS513 | Monoclonal antibody | 6 mg/kg | Intravenous |